- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
"中数随访时间为53.5个月期间" - 随访时间时间(< 5 年)太短! 预期下降也不是线性(linear)的.
最近的研究表明8年后HBsAg降至1000 iu /m l以下.
"Current clinical practice guidelines regard HBsAg seroclearance as the state of “functional cure”.2Previous studies showed that the predicted median time to HBsAg loss to be 36-52.2 years.4,7,8In HBV genotype D patients, a greater decline in HBsAg was observed in patients treated with more potent nucleos(t)ide analogue, such as entecavir or tenofovir, compared to telbivudine, with an estimated time to HBsAg loss of 17 years.3Although genotyping of the patients was not done, as genotype C predominates in 99% of HBV infected patients in Korea,10 the slower decline of quantitative HBsAg in our study may be representative of the decline in genotype C patients (74.1 and 73.5 years in HBeAg positive and negative patients, respectively).In this study, the difference in the quantitative HBsAg kinetics between HBeAg-positive and HBeAg-negative patients was not significant (p=0.48). On the contrary, a previous study reported a difference in the HBsAg kinetic patterns between HBeAg-positive and –negative patients.7The contradicting results of the kinetics based on the HBeAg-positivity warrants further studies. "
当前的临床实践指南将HBsAg血清清除视为“功能性治愈”状态。2以前的研究表明,预计HBsAg丧失的中位时间为36-52.2年。4、7、8在HBV基因型D患者中,HBsAg的下降幅度更大。与替比夫定相比,在用更有效的核苷酸类似物(例如恩替卡韦或替诺福韦)治疗的患者中观察到,HBsAg丧失的时间估计为17年。3尽管没有进行基因分型,因为在99例中基因C型居多在韩国HBV感染患者中所占的百分比[10],本研究中定量HBsAg的下降较慢可能代表了基因型C患者的下降(HBeAg阳性和阴性患者分别为74.1岁和73.5岁)。 HBeAg阳性和HBeAg阴性患者之间的定量HBsAg动力学并不显着(p = 0.48)。相反,以前的研究报道了HBeAg阳性和阴性患者之间HBsAg动力学模式的差异。7基于HBeAg阳性的动力学结果相互矛盾,值得进一步研究。 |
|